PT - JOURNAL ARTICLE AU - Nicholas G. Davies AU - Petra Klepac AU - Yang Liu AU - Kiesha Prem AU - Mark Jit AU - CMMID COVID-19 working group AU - Rosalind M Eggo TI - Age-dependent effects in the transmission and control of COVID-19 epidemics AID - 10.1101/2020.03.24.20043018 DP - 2020 Jan 01 TA - medRxiv PG - 2020.03.24.20043018 4099 - http://medrxiv.org/content/early/2020/05/03/2020.03.24.20043018.short 4100 - http://medrxiv.org/content/early/2020/05/03/2020.03.24.20043018.full AB - The COVID-19 pandemic has shown a markedly low proportion of cases among children. Age disparities in observed cases could be explained by children having lower susceptibility to infection, lower propensity to show clinical symptoms, or both. We evaluate these possibilities by fitting an age-structured mathematical model to epidemic data from six countries. We estimate that clinical symptoms occur in 25% (95% CrI: 19-32%) of infections in 10-19-year-olds, rising to 76% (68-82%) in over-70s, and that susceptibility to infection in under-20s is approximately half that of older adults. Accordingly, we find that interventions aimed at children may have a relatively small impact on total cases, particularly if the transmissibility of subclinical infections is low. The age-specific clinical fraction and susceptibility we have estimated has implications for the expected global burden of COVID-19 because of demographic differences across settings: in younger populations, the expected clinical attack rate would be lower, although it is likely that comorbidities in low-income countries will affect disease severity. Without effective control measures, regions with older populations may see disproportionally more clinical cases, particularly in the later stages of the pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge the following for funding: NGD: National Institutes of Health Research (HPRU-2012-10096). PK, YL, KP, MJ: This research was partly funded by the Bill & Melinda Gates Foundation (INV-003174). YL, MJ: This research was partly funded by the National Institute for Health Research (NIHR) (16/137/109) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care. RME: HDR UK (grant: MR/S003975/1). The members of the CMMID COVID-19 working group and the funding they acknowledge are: Carl A B Pearson, Billy J Quilty (NIHR 16/137/109), Adam J Kucharski (Wellcome Trust grant: 206250/Z/17/Z), Hamish Gibbs (funded by the Department of Health and Social Care using UK Aid funding and is managed by the NIHR. The views expressed in this publication are those of the author(s) and not necessarily those of the Department of Health and SocialCare (ITCRZ 03010), Samuel Clifford (Wellcome Trust grant: 208812/Z/17/Z), Amy Gimma (Global Challenges Research Fund (GCRF) for the project "RECAP" managed through RCUK and ESRC (ES/P010873/1), Kevin van Zandvoort (supported by Elrha’s Research for Health in Humanitarian Crises (R2HC) Programme, which aims to improve health outcomes by strengthening the evidence base for public health interventions in humanitarian crises. The R2HC programme is funded by the UK Government (DFID), the Wellcome Trust, and the UK National Institute for Health Research (NIHR), James D Munday (Wellcome Trust grant: 210758/Z/18/Z), Charlie Diamond (NIHR 16/137/109), W John Edmunds, Joel Hellewell (Wellcome Trust grant: 210758/Z/18/Z), Timothy W Russel (Wellcome Trust grant: 206250/Z/17/Z), Sam Abbott (Wellcome Trust grant: 210758/Z/18/Z), Sebastian Funk (Wellcome Trust grant: 210758/Z/18/Z), Nikos I Bosse, Fiona Sun (NIHR EPIC grant 16/137/109), Stefan Flasche (Wellcome Trust grant: 208812/Z/17/Z), Alicia Rosello (NIHR grant: PR-OD-1017-20002), Christopher I Jarvis (Global Challenges Research Fund (GCRF) project ‘RECAP’ managed through RCUK and ESRC (ES/P010873/1)), RMGJH (European Research Commission Starting Grant: #757699).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used for the analysis are publicly available. Analysis code will be made available on Github.